Literature DB >> 19815071

An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis.

F Loría1, S Petrosino, M Hernangómez, L Mestre, A Spagnolo, F Correa, V Di Marzo, F Docagne, C Guaza.   

Abstract

The aim of this study was to evaluate how endocannabinoids interact with excitotoxic processes both in vitro, using primary neural cell cultures, and in vivo, in the TMEV-IDD model of multiple sclerosis. First, we observed that neuronal cells respond to excitotoxic challenges by the production of endocannabinoid molecules which in turn exerted neuroprotective effects against excitotoxicity. The inhibitor of endocannabinoid uptake, UCM707, protected specifically against AMPA-induced excitotoxicity, by activating CB(1) and CB(2) cannabinoid receptors, as well as the nuclear factor, PPARgamma. This neuroprotective effect was reverted by blocking the glial glutamate transporter, GLT-1. Mice subjected to the model of multiple sclerosis showed a decrease in the expression of GLT-1. UCM707 reversed this loss of GLT-1 and induced a therapeutic effect. Our data indicate that the enhancement of the endocannabinoid tone leads to neuroprotection against AMPA-induced excitotoxicity and provides therapeutic effects in this model of multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19815071     DOI: 10.1016/j.nbd.2009.09.020

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  30 in total

Review 1.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

2.  PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis.

Authors:  L Mestre; M Redondo; F J Carrillo-Salinas; J A Morales-García; S Alonso-Gil; A Pérez-Castillo; C Gil; A Martínez; C Guaza
Journal:  Br J Pharmacol       Date:  2015-07-14       Impact factor: 8.739

Review 3.  The endocannabinoid system as a target for the treatment of neurodegenerative disease.

Authors:  Emma L Scotter; Mary E Abood; Michelle Glass
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

4.  2-Arachidonoylglycerol Reduces Proteoglycans and Enhances Remyelination in a Progressive Model of Demyelination.

Authors:  Ana Feliú; Itziar Bonilla Del Río; Francisco Javier Carrillo-Salinas; Gloria Hernández-Torres; Leyre Mestre; Nagore Puente; Silvia Ortega-Gutiérrez; Maria L López-Rodríguez; Pedro Grandes; Miriam Mecha; Carmen Guaza
Journal:  J Neurosci       Date:  2017-07-27       Impact factor: 6.167

5.  A Sativex(®) -like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis.

Authors:  A Feliú; M Moreno-Martet; M Mecha; F J Carrillo-Salinas; E de Lago; J Fernández-Ruiz; C Guaza
Journal:  Br J Pharmacol       Date:  2015-05-20       Impact factor: 8.739

6.  A synthetic cannabinoid agonist promotes oligodendrogliogenesis during viral encephalitis in rats.

Authors:  Marylou V Solbrig; Yijun Fan; Neal Hermanowicz; Maria Grazia Morgese; Andrea Giuffrida
Journal:  Exp Neurol       Date:  2010-09-09       Impact factor: 5.330

Review 7.  Is lipid signaling through cannabinoid 2 receptors part of a protective system?

Authors:  P Pacher; R Mechoulam
Journal:  Prog Lipid Res       Date:  2011-02-02       Impact factor: 16.195

8.  Regulatory role of cannabinoid receptor 1 in stress-induced excitotoxicity and neuroinflammation.

Authors:  Silvia Zoppi; Beatriz G Pérez Nievas; José L M Madrigal; Jorge Manzanares; Juan C Leza; Borja García-Bueno
Journal:  Neuropsychopharmacology       Date:  2010-12-08       Impact factor: 7.853

9.  Regulatory role of the cannabinoid CB2 receptor in stress-induced neuroinflammation in mice.

Authors:  S Zoppi; J L Madrigal; J R Caso; M S García-Gutiérrez; J Manzanares; J C Leza; B García-Bueno
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

Review 10.  Modulating the endocannabinoid system in human health and disease--successes and failures.

Authors:  Pál Pacher; George Kunos
Journal:  FEBS J       Date:  2013-04-22       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.